ACM
ASBPW

Atalaya Capital Management’s Aspire Biopharma Warrant ASBPW Stock Holding History

Atalaya Capital Management’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$1.5K Hold
50,000
– – ﹤0.01% 83
2024
Q1 		$1.5K Hold
50,000
– – ﹤0.01% 103
2023
Q4 		$3K Hold
50,000
– – ﹤0.01% 91
2023
Q3 		$2.5K Hold
50,000
– – ﹤0.01% 122
2023
Q2 		$2.5K Hold
50,000
– – ﹤0.01% 148
2023
Q1 		$2K Hold
50,000
– – ﹤0.01% 207
2022
Q4 		$4K Hold
50,000
– – ﹤0.01% 228
2022
Q3 		$9K Buy
+50,000
New +$7.28K ﹤0.01% 289

Other funds holding ASBPW

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Atalaya Capital Management's ASBPW Position: Q2 2024 in Review

Atalaya Capital Management held its Aspire Biopharma Warrant (ASBPW) position steady in Q2 2024 at 50,000 shares worth $1.5K. The position accounts for ﹤0.01% of the portfolio, ranked #83.

Atalaya Capital Management first reported a position in ASBPW in Q3 2022 and has held it in 8 quarters since. The position peaked at $9K in Q3 2022. 33 funds tracked by Wall St. Rank hold ASBPW as of Q2 2024.

  • Atalaya Capital Management held 50,000 shares of Aspire Biopharma Warrant worth $1.5K as of Q2 2024.
  • Atalaya Capital Management left its Aspire Biopharma Warrant share count unchanged in Q2 2024.
  • Aspire Biopharma Warrant made up ﹤0.01% of Atalaya Capital Management's portfolio in Q2 2024, its #83 holding.
  • Atalaya Capital Management first reported a position in Aspire Biopharma Warrant in Q3 2022 and has held it in 8 quarters since.
  • Atalaya Capital Management's Aspire Biopharma Warrant position peaked at $9K in Q3 2022.
  • 33 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2024.

Based on Atalaya Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.